PT  - JOURNAL ARTICLE
AU  - Khan, Muhammad S.
AU  - Kyriakopoulos, Christos P.
AU  - Taleb, Iosif
AU  - Dranow, Elizabeth
AU  - Scott, Monte
AU  - Ranjan, Ravi
AU  - Yin, Michael
AU  - Tseliou, Eleni
AU  - Alharethi, Rami
AU  - Caine, William
AU  - Shaw, Robin M.
AU  - Selzman, Craig H.
AU  - Drakos, Stavros G.
AU  - Dosdall, Derek J.
TI  - Baseline QRS Duration Associates with Cardiac Recovery in Patients with Continuous-Flow Left Ventricular Assist Device Implantation
AID  - 10.1101/2021.09.21.21263287
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.21.21263287
4099  - http://medrxiv.org/content/early/2021/09/23/2021.09.21.21263287.short
4100  - http://medrxiv.org/content/early/2021/09/23/2021.09.21.21263287.full
AB  - BACKGROUND In chronic heart failure (HF) patients supported with continuous-flow left ventricular assist device (CF-LVAD), we aimed to assess the clinical association of baseline QRS duration (QRSd) with post-LVAD cardiac recovery, and its correlation with pre- to post-LVAD change in left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDD).METHODS Chronic HF patients (n=402) undergoing CF-LVAD implantation were prospectively enrolled, at one of the centers comprising the U.T.A.H. (Utah Transplant Affiliated Hospitals) consortium. After excluding patients with acute HF etiologies, hypertrophic or infiltrative cardiomyopathy, and/or inadequate post-LVAD follow up (<3 months), 315 patients were included in the study. Cardiac recovery was defined as LVEF ≥40% and LVEDD <6 cm within 12 months post-LVAD implantation. Patients fulfilling this condition were termed as responders (R) and results were compared with non-responders (NR).RESULTS Thirty-five patients (11%) achieved ‘R’ criteria, and exhibited a 15% shorter QRSd compared to ‘NR’ (123±37 ms vs 145±36 ms; p<0.001). A univariate analysis identified association of baseline QRSd with post-LVAD cardiac recovery (OR:0.986, 95% CI:0.976-0.996, p<0.001). In a multivariate logistic regression model, after adjusting for duration of HF (OR:0.990, 95% CI:0.983-0.997, p=0.006) and gender (OR:0.388, 95% CI:0.160-0.943, p=0.037), pre-LVAD QRSd exhibited a significant association with post-LVAD cardiac structural and functional improvement (OR:0.987, 95% CI:0.977-0.998, p=0.027) and the predictive model showed a c-statistic of 0.73 with p<0.001. The correlations for baseline QRSd with pre- to post-LVAD change in LVEF and LVEDD were also investigated in ‘R’ and ‘NR’ groups.CONCLUSION Chronic advanced HF patients with a shorter baseline QRSd exhibit an increased potential for cardiac recovery after LVAD support.Competing Interest StatementRR is a consultant for Abbott, Medtronic, and Biosense Webster. All other authors have no relevant financial or non-financial interests to disclose.Funding StatementThe research has been supported by NHLBI of NIH under award: 5R01HL128752 (DJD), R01HL135121-01 (SGD), R01HL132067-01A1 (SGD), AHA Heart Failure Strategically Focused Research Network 16SFRN29020000 (SGD), Merit Review Award I01 CX002291 U.S. Dept. of Veterans Affairs (SGD) and a research grant from the Nora Eccles Treadwell Foundation (DJD and SGD). MSK and IT are supported through NHLBI postdoctoral training grant T32HL007576. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, Dept. of Veterans Affairs and AHA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institute Review Board (IRB) -The University of Utah, Salt Lake City, UT 84112. Ethical approval was given, and the patients were prospectively enrolled. Informed consent was obtained under the IRB 30622 - "Effects of Mechanical Unloading on Myocardial Function and Structure in Humans study."All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.(AF)Atrial fibrillation(ALT)Alanine aminotransferase(AST)Aspartate aminotransferase(ALP)Alkaline phosphatase(ACEI)Angiotensin-converting-enzyme inhibitor(ARB)Angiotensin receptor blockers(BUN)Blood urea nitrogen(BNP)Brain natriuretic peptide(BSA)Body surface area(BMI)Body mass index(CI)Cardiac index(Cr)Creatinine(HR)Heart rate(Hb)Hemoglobin(IABP)Intra-aortic balloon pump(IVSD)Inter ventricular septal diameter(LVEF)Left ventricular ejection fraction(LVEDD)Left ventricular end-diastolic diameter(LVESD)Left ventricular end-systolic diameter(MCS)Mechanical circulatory support(RAP)Right atrial pressure(PAP)Pulmonary atrial pressure(PCWP)Pulmonary capillary wedge pressure(PVR)Pulmonary vascular resistance(RVSWI)Right ventricular stroke work index(SVR)Systemic vascular resistance(TR)Tricuspid regurgitation